Soleus Capital Management L.P. decreased its stake in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 47.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,262,026 shares of the company's stock after selling 2,026,141 shares during the period. Soleus Capital Management L.P. owned about 5.10% of ESSA Pharma worth $4,049,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Tang Capital Management LLC bought a new stake in ESSA Pharma during the fourth quarter worth $7,697,000. BML Capital Management LLC bought a new stake in ESSA Pharma during the fourth quarter worth $7,557,000. Altium Capital Management LLC bought a new stake in ESSA Pharma during the fourth quarter worth $2,556,000. Bank of America Corp DE lifted its holdings in ESSA Pharma by 10,153,775.0% during the fourth quarter. Bank of America Corp DE now owns 812,310 shares of the company's stock worth $1,454,000 after acquiring an additional 812,302 shares during the period. Finally, Aldebaran Capital LLC bought a new stake in ESSA Pharma during the fourth quarter worth $712,000. Hedge funds and other institutional investors own 75.12% of the company's stock.
ESSA Pharma Stock Up 1.8%
ESSA Pharma stock traded up $0.03 during mid-day trading on Friday, reaching $1.69. 9,320 shares of the company's stock were exchanged, compared to its average volume of 338,641. The business's fifty day simple moving average is $1.65 and its 200 day simple moving average is $1.70. The firm has a market capitalization of $75.02 million, a PE ratio of -2.45 and a beta of 1.69. ESSA Pharma Inc. has a one year low of $1.40 and a one year high of $7.88.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. On average, sell-side analysts forecast that ESSA Pharma Inc. will post -0.42 earnings per share for the current year.
ESSA Pharma Profile
(
Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
See Also
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
